{"id":"https://openalex.org/W2590421993","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4042","title":"Phase II pharmacokinetic (PK) and pharmacodynamic (PD) study of OSI-7904L in previously untreated patients (pts) with advanced gastric or gastroesophageal junction cancer (G/GEJC)","display_name":"Phase II pharmacokinetic (PK) and pharmacodynamic (PD) study of OSI-7904L in previously untreated patients (pts) with advanced gastric or gastroesophageal junction cancer (G/GEJC)","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2590421993","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4042","mag":"2590421993"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.4042","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4042","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4042","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010914696","display_name":"Stephen J. Falk","orcid":"https://orcid.org/0000-0001-6106-3062","observed_orcids":["https://orcid.org/0000-0001-6106-3062"]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. J. Falk","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080693514","display_name":"Alan Anthoney","orcid":"https://orcid.org/0000-0001-5695-8312","observed_orcids":["https://orcid.org/0000-0001-5695-8312"]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Anthoney","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113728574","display_name":"Martin McKinlay Eatock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Eatock","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090645179","display_name":"Eric Van Cutsem","orcid":"https://orcid.org/0000-0002-6372-1230","observed_orcids":["https://orcid.org/0000-0002-6372-1230"]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E. van Cutsem","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088102157","display_name":"James C. Evans","orcid":"https://orcid.org/0000-0003-2383-8984","observed_orcids":["https://orcid.org/0000-0003-2383-8984"]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Evans","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077826150","display_name":"Juan W. Valle","orcid":"https://orcid.org/0000-0002-1999-0863","observed_orcids":["https://orcid.org/0000-0002-1999-0863","https://orcid.org/0000-0002-7964-8402"]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Valle","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111992869","display_name":"J. Chick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Chick","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102948810","display_name":"Daniel W. Drolet","orcid":"https://orcid.org/0000-0002-1877-0092","observed_orcids":["https://orcid.org/0000-0002-1877-0092"]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Drolet","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107447211","display_name":"D. Ferry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Ferry","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044064524","display_name":"Jaffer A. Ajani","orcid":"https://orcid.org/0000-0001-9946-0629","observed_orcids":["https://orcid.org/0000-0001-9946-0629"]},"institutions":[{"id":"https://openalex.org/I2799762726","display_name":"New Cross Hospital","ror":"https://ror.org/05w3e4z48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799762726","https://openalex.org/I4210154310"]},{"id":"https://openalex.org/I2802808109","display_name":"Belfast City Hospital","ror":"https://ror.org/02405mj67","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I2802808109"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Ajani","raw_affiliation_strings":["Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Oncology Ctr, Bristol, United Kingdom; Cookridge Hosp, Leeds, United Kingdom; Belfast City Hosp, Belfast, United Kingdom; Univ Hosp, Leuven, Belgium; Beatson Oncology Ctr, Glasgow, United Kingdom; Christie Hosp, Manchester, United Kingdom; OSI Pharmaceuticals, Oxford, United Kingdom; OSI Pharmaceuticals, Boulder, CO; New Cross Hosp, Wolverhampton, United Kingdom; M.D. Anderson, Houston, TX","institution_ids":["https://openalex.org/I2799762726","https://openalex.org/I2802808109"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"4042","last_page":"4042"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.9437999725341797,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.9437999725341797,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0284000001847744,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.006599999964237213,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-gastric-cancer","display_name":"advanced gastric cancer","score":0.8619999885559082},{"id":"https://openalex.org/keywords/gastroesophageal-junction-cancer","display_name":"gastroesophageal junction cancer","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9810000061988831},{"id":"https://openalex.org/keywords/2-deoxyuridine","display_name":"2'-deoxyuridine","score":0.9079999923706055},{"id":"https://openalex.org/keywords/homocysteine","display_name":"homocysteine","score":0.9900000095367432},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.5479999780654907},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7630000114440918},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8259999752044678},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.4830000102519989}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9388479590415955},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6639681458473206},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6625158786773682},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6482913494110107},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.5787593126296997},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4847671389579773},{"id":"https://openalex.org/C2779051857","wikidata":"https://www.wikidata.org/wiki/Q911386","display_name":"Stomatitis","level":2,"score":0.4815388321876526},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45484623312950134},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3894061744213104},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.38249143958091736}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.4042","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4042","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4042","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1966095507","https://openalex.org/W7095343627","https://openalex.org/W2034129053","https://openalex.org/W2131757802","https://openalex.org/W1976117205","https://openalex.org/W2104153152","https://openalex.org/W2073000870","https://openalex.org/W4243057980","https://openalex.org/W7112370039","https://openalex.org/W4243840147"],"abstract_inverted_index":{"4042":[0],"Background:":[1],"OSI-7904L":[2,35,282],"is":[3,283],"a":[4,274],"liposomal":[5],"TS":[6,263],"inhibitor":[7],"with":[8,166,187,243,253,288,293],"increased":[9,304],"plasma":[10],"residence":[11],"and":[12,63,78,85,105,119,137,211,228,237,265,290,301],"superior":[13],"preclinical":[14],"antitumor":[15],"activity":[16,33],"compared":[17],"to":[18,30,74],"parent":[19],"drug":[20],"or":[21,128,315,318],"5-FU.":[22],"Methods:":[23],"A":[24],"2-stage":[25],"Simon":[26],"design":[27],"was":[28,97,113,180,205,299,307],"used":[29],"evaluate":[31],"the":[32],"of":[34,89,117,124,133,148,276],"in":[36,115,121,190,241,285],"G/GEJC,":[37,53],"administered":[38],"at":[39],"12":[40],"mg/m2":[41],"over":[42],"30":[43],"min":[44],"every":[45],"21":[46],"days.":[47],"Eligibility":[48],"criteria":[49],"included":[50],"pathologically":[51],"confirmed":[52],"ECOG":[54,108],"PS":[55,109],"0\u20132,":[56],"no":[57],"prior":[58],"chemo":[59],"for":[60,158],"advanced":[61,286],"disease":[62],"\u22651":[64],"measurable":[65],"lesion":[66],"per":[67],"RECIST.":[68],"Secondary":[69],"endpoints":[70,81],"were":[71,93,103,135,214,221],"safety,":[72],"time":[73],"progression":[75],"(TTP),":[76],"survival":[77],"PK/":[79],"PD":[80],"(TS":[82],"genotype,":[83],"2\u2019-dU":[84,266],"homocysteine).":[86],"Results:":[87],"Fifty":[88],"53":[90],"enrolled":[91],"pts":[92,118,125,153,174,195,242,277],"treated.":[94],"Median":[95,203],"age":[96],"64":[98],"years":[99],"(range":[100,150],"35\u201382),":[101],"62%":[102],"male":[104],"90%":[106],"had":[107,126,175,197],"0/1.":[110],"Primary":[111],"site":[112],"gastric":[114],"80%":[116],"GEJ":[120],"20%.":[122],"Two-thirds":[123],"recurrent":[127],"metastatic":[129],"disease;":[130],"main":[131,217],"sites":[132],"metastases":[134],"liver":[136],"lymph":[138],"node.":[139],"To":[140],"date,":[141],"215":[142],"cycles":[143],"have":[144],"been":[145],"given,":[146],"median":[147],"4/pt":[149],"1\u201312+).":[151],"Eleven":[152],"required":[154],"dose":[155,247],"reductions,":[156],"mainly":[157],"skin":[159],"toxicity":[160,245],"(8":[161],"pts).":[162],"Reductions":[163],"and/or":[164,246],"prophylaxis":[165],"dexamethasone":[167,302],"ameliorated":[168],"symptoms,":[169],"permitting":[170],"further":[171],"treatment.":[172],"Seven":[173],"cycle":[176,260],"delays.":[177],"The":[178,216],"ORR":[179,289],"15%":[181],"(95%":[182],"CI":[183],"6.2":[184],"-":[185],"28.3)":[186],"7":[188],"PRs":[189],"47":[191],"evaluable":[192],"pts.":[193],"Twenty-three":[194],"(49%)":[196],"SD":[198],"including":[199],"several":[200],"minor":[201],"responses.":[202],"TTP":[204,291],"17":[206],"weeks.":[207],"G3/4":[208,218,244],"neutropenia":[209],"(14%)":[210],"thrombocytopenia":[212],"(4%)":[213],"uncommon.":[215],"nonhematological":[219],"toxicities":[220],"skin-related":[222],"20%,":[223],"fatigue":[224],"19%,":[225],"mucositis/stomatitis":[226],"16%":[227],"diarrhea":[229],"9%.":[230],"PK":[231],"data":[232],"showed":[233],"high":[234],"interpatient":[235],"variability":[236],"significantly":[238],"higher":[239],"AUC":[240],"reductions.":[248],"Response":[249],"did":[250,257],"not":[251,258],"correlate":[252],"AUC.":[254],"Baseline":[255],"homocysteine":[256],"influence":[259],"1":[261],"toxicity.":[262],"genotype":[264],"elevations":[267],"as":[268,270],"well":[269],"tumor":[271],"biopsies":[272],"from":[273],"subset":[275],"are":[278],"being":[279],"analyzed.":[280],"Conclusions:":[281],"active":[284],"G/GEJC":[287],"comparable":[292],"other":[294],"single":[295],"agents.":[296],"Safety":[297],"profile":[298],"favorable":[300],"premedication":[303],"tolerability.":[305],"Study":[306],"funded":[308],"by":[309],"OSI":[310,330,331,332,333,334],"Pharmaceuticals.":[311],"Author":[312],"Disclosure":[313],"Employment":[314],"Leadership":[316],"Consultant":[317],"Advisory":[319],"Role":[320],"Stock":[321],"Ownership":[322],"Honoraria":[323],"Research":[324],"Funding":[325],"Expert":[326],"Testimony":[327],"Other":[328],"Remuneration":[329]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-03-03T00:00:00"}